Clinical trial
Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients…
NCT00378209 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00378209 |
|---|---|
| Title | Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma |
| Official title | Am Open-Label Phase II Study of the Safety and Efficacy of Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Brigham and Women's Hospital Massachusetts General Hospital Celgene Corporation Industry Millennium Pharmaceuticals, Inc. |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Bortezomib, Lenalidomide, Dexamethasone |
| Enrollment | 65 |
| Start date | Aug 1, 2006 |
| Primary completion | Oct 1, 2012 |
| Completion | Oct 1, 2016 |
| First posted | Sep 19, 2006 |
| Last update posted | Nov 17, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: